Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sleepy Tuesday....bounce will come.
$ABPI $$$$$$
It can't run if their are no buyers. If everyone just sits and waits, then nothing moves.
Patience will pay here! Huge run extremely likely.....GOOD THINGS COME TO THOSE WHO WAIT!!!
$ABPI BOOOOOOM
Patience will pay here! Huge run extremely likely.....GOOD THINGS COME TO THOSE WHO WAIT!!!
$ABPI BOOOOOOM
Getting close now. Hold on tight guys. Set your sells high. This baby is super thin.
Time for some upward momentum here!
Go $ ABPI!!
Great find!!! Let's go ABPI!
Patent News
http://www.highbeam.com/doc/1P3-3249118561.html
Someone know out the 79's and see if we can close around 1 today. That would be huge.
We need a big group to alert this. A couple more 6 million volume days will send this to the moon.hopefully this will hold above the 200 day moving average and bounces. If not I can see it dipping below the 50 day moving average and settling around the 20's until we get a PR. Hopefully I'm wrong, because I'm holding some bags.
Can anyone post a L2? Curious to see what direction we are going in today. Thanks
Charts and technicals don't mean much when new developments are taking place. It looks like the company is getting ready to become more transparent, and what I see is some very expensive equipment that could help with large scale deployments of vaccines for contagious diseases, like Ebola????
Easy but I think it won't stop there I think this may be heading for much higher than .10
So right Caffeine! ! This is so thin it could rip to .10 in a blink. Holding strong.
Go $ ABPI
Charts have often been wrong about sectors such as this. I mean, if you followed the Marijuana Sector during Janurary - March, Charts were wrong almost (if not all) all the time.
Imagine if you sold early on that run, imagine how many THOUSANDS of Percent you would have lost, if you followed the Charts?
The Ebola sector is one of the sectors where charts do not apply. Thanks for the work though.
$ABPI -daily chart. I would be careful here, trading at upper BB and >EMA, A/D and C/O falling fast
BigCheds
I can't believe the price of the stock, at this level...
It's due for at least a reversal back to a copper(.05), than a dime (.10)
Biovest is collaborating with the U.S. Department of Defense (“DoD”) and others to further develop AutovaxID and Biovest’s related hollow fiber systems and to explore potential production of additional vaccines, including vaccines for viral indications such as influenza and other contagious diseases.
Taken from the 10-Q Feb, 2013
Hope this moves slowly this week so there is no major sell off. I have a feeling big things are coming for those who wait. Load up!!
Thats awesome news. We been holding well here. Boom coming!!
GO ABPI
It looks like Biovest is rapidly updating their new site on their hollow fiber instruments, just 4 days ago the website was just a landing page that said hollow fiber coming soon. Now some pages are complete, possibly filings and news to come soon, obviously something is coming and it might be huge.
http://hollow-fiber.com/
Is it monday yet!? People have been loading bc they KNOW this is gonna pop. Monster run ahead.... Either u get in and join the party or watch from the sidelines!
BioVest settled a lawsuit filed against them for 1.25 million, on September 5th, 2014. Just saying.
Crappy day overall. Slow volume....Monday starts a new week.
No volume + plus no bid support = weekend beer money. What a shame
Last 30 min of trading less do this and blow past out first resistance at .0117. L2 anyone?
Looks like she is ready to rip!
$Volume Picking Up$
Promotion campaigne happening soon.
Looks like is ready ;)
$HEAVY SUPPORT$
THIN LEVEL 2 TILL COPPER. THAT MEANS $$$$$$$
Sleepy Friday. Need a slap attack!!
Go ABPI $$$$$$$
Looking to be a huge Friday for $ABPI!!
Come on with the volume!!!
Here are the promotions!!! They are starting to roll in. BIG BIG money coming in!!!!!
http://www.pennystockdream.com/blog/abpi-accentia-biopharmaceuticals-inc-has-gained-158750-in-the-past-3-days
http://www.pennystockdream.com/blog/abpi-accentia-biopharmaceuticals-inc-has-gained-158750-in-the-past-3-days
This was being posted hundreds of times yesterday. People are definitely aware and loading!
$ABPI BREAKOUT COMING.
GOING TO RETeST .0275 AGAIN, BREAKOUT TILL COPPER .05!
Yup is looking good for those holding this stock ;)
Probably going to coincide with a barrage of news
Good Luck, Thanks for the heads up :)
More money for us!
New Coming IMO,
Also, some notes to know, they are working with a GOVERNMENT AGENCY to produce this EBOLA CURE/TREATMENT!
Im hearing a promoter is going to pump this stock soon. Just a heads up.
Haha true true :) ABPI is gonna be great tomorrow! I have a feeling... I just know it!
Maybe not a run that high... But certainly someone was loading.
I called this at .008,
GOOD LUCK~
Someone was definitely loading today....... Tomorrow is gonna be exciting! Lookin for that 1000000% runner lol...
ABPI
;) Keep an eye out for this one.
EBOLA is especially hot right now in the market. The trading here (and on many other stocks) have been reflecting the Marijuana Market Bubble run, where it will run 200-300% on the first few days, then retract 50%.
But you know what happened afterwords? EACH and EVERYONE of those stocks soon ran another 1000-2000%. Some ran as high as 45,000% from their 52-week low...
Good luck!
Looking that way!! Thanks again.
Agreed, Caffeine!! We gonna rock this ticker....in at the front. BONUS!!!
GO ABPI !!!
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
677
|
Created
|
09/03/05
|
Type
|
Free
|
Moderators |
TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that Biovest and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) have entered into a Cooperative Research and Development Agreement (CRADA) to further develop Biovest’s hollow fiber perfusion bioreactors as a flexible and modular manufacturing platform for the rapid, robust and cost-effective production of medical countermeasures to emerging and genetically engineered infectious diseases. This CRADA utilizes Biovest’s hollow fiber technology for production of vaccines, virus-like particles (VLPs) and antibodies for treatment and prevention of filovirus diseases including those caused by Ebola and Marburg viruses.
“Our instrumentation is uniquely designed for the commercial manufacture of personalized medicines and vaccines. This vast potential is now being evaluated in three very important collaborations with the Naval Health Research Center, Max Planck Institute and USAMRIID”
According to Biovest’s consulting medical advisor, J. David Gangemi, Ph.D., Professor Emeritus, Microbiology and Molecular Medicine, Clemson University, “Biovest’s collaboration with USAMRIID is part of a large U.S. government priority investment to become fully prepared for the swift and efficient delivery of medical countermeasures to highly infectious agents including avian and swine influenza, and other emerging diseases. Expanding on the positive influenza virus data generated under Biovest’s CRADA with the Naval Health Research Center, our collaboration with Army’s infectious disease research team aims to demonstrate the utility and agility of Biovest’s hollow fiber bioreactors to propagate infectious virus for vaccine production and to validate the production of VLPs and virus neutralizing antibodies.”
Biovest’s patented hollow fiber bioreactor systems are compact, scalable and economical for large-scale virus and antibody production. In contrast to other systems, Biovest’s technology provides multiple benefits including: 1) controlled culture conditions with high cell density attained; 2) space efficiency and high-yield production; and 3) selective dilution/removal of inhibitory byproducts.
“Our instrumentation is uniquely designed for the commercial manufacture of personalized medicines and vaccines. This vast potential is now being evaluated in three very important collaborations with the Naval Health Research Center, Max Planck Institute and USAMRIID,” stated, Biovest’s Chief Science Officer, Mark Hirschel, Ph.D. “And we are continuing to pursue other strategic partnerships within the U.S. Department of Defense and with other leading research institutions worldwide to establish Biovest’s biomanufacturing technology as an optimal cell culture platform for the production of many kinds of cell-based biologic therapies.”
AutovaxID® is an automated, self-contained, scalable system that employs a single-use, hollow-fiber bioreactor for cell expansion. Since it is functionally closed, computer-controlled and fully-automated, operation of the AutovaxID requires limited supervision and minimal manpower compared to other systems. The AutovaxID is a flexible system, uniquely designed to address a variety of biotechnology and pharmaceutical applications.
Been in development for over 2 YEARS. This company has been in the development a treatment for over 2 years, much more than those JUST OTC companies coming into the market just now.MINNEAPOLIS & TAMPA, Fla.--(BUSINESS WIRE)--
Biovest International, Inc. (“Biovest”), a leader and a pioneer in the development of personalized cancer immunotherapies, today announced that Biovest’s Chief Executive Officer, Carlos F. Santos, Ph.D., will deliver the keynote presentation at the Phacilitate Immunotherapy Forum (part of Phacilitate’s Washington Bioleaders 2014 Conference) taking place at the Grand Hyatt Hotel on January 27-29, 2014 in Washington, D.C. The keynote presentation on Monday, January 27, 2014 is titled “The Integration of Clinical Bioinformatics, Automated Cell Culture, and Automated Manufacturing for the Rapid Development of Personalized Lymphoma Vaccines”, and Dr. Santos will be a panelist for the corresponding discussion session. Dr. Santos will serve as the chair and moderator of the Tuesday, January 28, 2014 morning plenary session of the Immunotherapy Forum. He will also make a presentation titled "Case Study: Making the Personal Affordable: Efficient Manufacture of Autologous Cancer Immunotherapies”, and will act as an informal panelist for the panel discussion to follow. On the final day of the Conference, January 29, 2014, Dr. Santos will present "Case Studies of Personalized Immunotherapies in Development – Examining Trial Designs and Biomarker R&D Strategies – Case Study 3”.
“This forum provides us an excellent opportunity to advance personalized immunotherapy and interact with leaders in the fields of cancer vaccines, cell and gene therapy, and biologics manufacturing,” said Dr. Santos. “At Biovest, we have developed a highly personalized, tumor-matched cancer vaccine (BiovaxID; dasiprotimut-T) to fight non-Hodgkin’s lymphoma. As part of our efforts in bringing this vaccine to market, we have also pioneered highly automated systems for biomanufacturing of personalized medicines. We believe these advances, together with the clinical informatics and biomarker data which accompanies each of our vaccines, will ultimately make cancer vaccines much more accessible for patients diagnosed with non-Hodgkin’s lymphoma.”
Robert E. Farrell, J.D., Biovest’s Chief Financial Officer, will be presenting at the Personalized Medicines World Conference of Silicon Valley on January 27-28, 2014. Mr. Farrell’s presentation, “Automated Systems for Personal-Scale Manufacture of Commercial Cancer Vaccines“, will take place on January 28, 2014 at 8:45 AM PST at the Computer History Museum in Mountain View, CA. Mr. Farrell stated, “both of these conferences will present substantial exposure for Biovest’s immunotherapy program and provide an exciting opportunity to network with the biotechnology, personalized medicine, active immunotherapy, and investment communities. They provide outstanding venues in which to display our pioneering advances in personalized cancer vaccines.”
About Biovest International, Inc.
Biovest International, Inc. develops autologous active immunotherapies (personalized cancer vaccines) to treat B-cell non-Hodgkin’s lymphomas, which are cancers of the immune system. The Company’s lead personalized cancer vaccine candidate, BiovaxID, has undergone three clinical trials conducted in collaboration with the U.S. National Cancer Institute (NCI) that have demonstrated BiovaxID’s ability to increase the duration of cancer remission following chemotherapy and to induce immune responses which correlate highly with long-term survival. Biovest is currently in the process of pursuing European marketing approval for BiovaxID.
Accentia Biopharmaceuticals, Inc., a biotechnology company, engages in the development and commercialization of biopharmaceutical products in the United States. It develops Cyrevia as a system of care for the treatment of autoimmune diseases; SinuNasal lavage system as a medical device for the treatment of chronic sinusitis; and BiovaxID as a personalized therapeutic cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, mantle cell lymphoma, and other B-cell cancers. The company also sells hollow-fiber perfusion instruments used for the production of significant quantities of cell culture products, including AutovaxID, an automated cell culture production instrument an instrument for the production of cancer vaccines and other personalized medicines; Primer HF, a hollow-fiber cell culture system for producing small quantities of monoclonal antibody; miniMax and Maximizer for use in the production of mammalian cell secreted proteins; XCellerator, a self-standing floor system to support production protein; Multi-6, a cell culture system for producing six monoclonal antibodies; and hollow-fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. It has collaboration with the United States Department of Defense to develop AutovaxID and to explore potential production of additional vaccines, including vaccines for viral indications, such as influenza. The company was founded in 2002 and is headquartered in Tampa, Florida.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |